** Shares of drugmaker Emergent Biosolutions EBS.N rise 2.9% to $6.40 premarket
** EBS says U.S. Department of Health and Human Services has awarded it $62.4 million through contract modification to stockpile co's botulism treatment
** Modification has been made to existing 10-year contract whereby co will supply treatment called BAT
** Up to last close, stock had fallen 34.9% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))